Investors Could Be Concerned With Sichuan Hebang Biotechnology's (SHSE:603077) Returns On Capital

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an eye out for. Ideally, a business will show two trends; firstly a growing return on capital employed (ROCE) and secondly, an increasing amount of capital employed. Ultimately, this demonstrates that it's a business that is reinvesting profits at increasing rates of return. Having said that, from a first glance at Sichuan Hebang Biotechnology (SHSE:603077) we aren't jumping out of our chairs at how returns are trending, but let's have a deeper look.

Understanding Return On Capital Employed (ROCE)

For those that aren't sure what ROCE is, it measures the amount of pre-tax profits a company can generate from the capital employed in its business. To calculate this metric for Sichuan Hebang Biotechnology, this is the formula:

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)

0.028 = CN¥565m ÷ (CN¥26b - CN¥5.8b) (Based on the trailing twelve months to September 2024).

So, Sichuan Hebang Biotechnology has an ROCE of 2.8%. In absolute terms, that's a low return and it also under-performs the Chemicals industry average of 5.5%.

Check out our latest analysis for Sichuan Hebang Biotechnology

Historical performance is a great place to start when researching a stock so above you can see the gauge for Sichuan Hebang Biotechnology's ROCE against it's prior returns. If you're interested in investigating Sichuan Hebang Biotechnology's past further, check out this free graph covering Sichuan Hebang Biotechnology's past earnings, revenue and cash flow.

What The Trend Of ROCE Can Tell Us

On the surface, the trend of ROCE at Sichuan Hebang Biotechnology doesn't inspire confidence. To be more specific, ROCE has fallen from 5.4% over the last five years. However it looks like Sichuan Hebang Biotechnology might be reinvesting for long term growth because while capital employed has increased, the company's sales haven't changed much in the last 12 months. It's worth keeping an eye on the company's earnings from here on to see if these investments do end up contributing to the bottom line.

Our Take On Sichuan Hebang Biotechnology's ROCE

To conclude, we've found that Sichuan Hebang Biotechnology is reinvesting in the business, but returns have been falling. Unsurprisingly, the stock has only gained 29% over the last five years, which potentially indicates that investors are accounting for this going forward. As a result, if you're hunting for a multi-bagger, we think you'd have more luck elsewhere.

Like most companies, Sichuan Hebang Biotechnology does come with some risks, and we've found 2 warning signs that you should be aware of.

While Sichuan Hebang Biotechnology isn't earning the highest return, check out this free list of companies that are earning high returns on equity with solid balance sheets.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.